Halozyme Therapeutics, Inc. filed a Form 8-K on September 22, 2026, reporting the completion of its sale of $1,500.0 million aggregate principal amount of 1.50% Convertible Senior Notes due 2033, including the exercise of the initial purchasers' option for an additional $200.0 million.
Key Highlights
- Total offering size: $1,500.0 million aggregate principal amount of 1.50% Convertible Senior Notes due 2033, including $200.0 million from exercise of the initial purchasers' option.
- Net proceeds: Approximately $1,471.1 million after deducting initial purchasers' discounts, commissions, and estimated offering expenses.
- Capped Call Transactions: Approximately $187.5 million of net proceeds was used to fund the cost of entering into Capped Call Transactions.
- Existing note repurchases: The company expects to use a portion of proceeds to repurchase approximately $151.7 million of its 0.25% convertible senior notes due 2027 and approximately $220.0 million of its 1.00% convertible senior notes due 2028.
- Conversion terms: Initial conversion rate of 7.1509 shares per $1,000 principal amount, equivalent to a conversion price of approximately $139.84 per share.
- Interest payments: Semi-annually in arrears on April 1 and October 1 each year, beginning April 1, 2027, at an annual rate of 1.50%.
- Optional redemption: Redeemable at the company's option on or after October 7, 2030, subject to conditions including the stock price exceeding 130% of the conversion price.
Halozyme Closes $1.5 Billion Convertible Note Offering and Plans Debt Repurchases
According to the filing, Halozyme Therapeutics, Inc. (NASDAQ:HALO) completed the sale of $1,500.0 million in 1.50% Convertible Senior Notes due 2033 on September 22, 2026. The notes were issued under an indenture dated the same day, with The Bank of New York Mellon Trust Company, N.A. serving as trustee. The company disclosed that the notes were offered and sold to "qualified institutional buyers" pursuant to Rule 144A under the Securities Act of 1933, as amended, and have not been registered under the Securities Act or the securities laws of any other jurisdiction.
The company reported net proceeds of approximately $1,471.1 million. Of that amount, approximately $187.5 million was used to fund Capped Call Transactions. The filing states that the company expects to use a portion of proceeds to repurchase approximately $151.7 million principal amount of its 0.25% convertible senior notes due 2027, at a total repurchase cost including accrued and unpaid interest of approximately $217.0 million, and approximately $220.0 million principal amount of its 1.00% convertible senior notes due 2028, at a total repurchase cost including accrued and unpaid interest of approximately $435.5 million. These repurchases are to be effected through privately negotiated transactions. The company disclosed its intention to use the remaining proceeds for general corporate purposes, including working capital, capital expenditures, potential acquisitions and strategic transactions, and potentially future note repurchases or repayment at maturity.
The notes are unsecured obligations and, according to the filing, will rank equally in right of payment with the company's existing and future liabilities that are not expressly subordinated, will be effectively junior to any secured indebtedness to the extent of the value of securing assets, and will be structurally subordinated to all indebtedness and other liabilities of current or future subsidiaries. Holders may convert the notes under specified conditions prior to April 1, 2033, and at any time from April 1, 2033 until the second scheduled trading day before maturity. Upon a Fundamental Change, holders may require the company to repurchase their notes for cash at 100% of principal plus accrued and unpaid interest.
What Was Disclosed
Halozyme reported the closing of a $1,500.0 million convertible note offering at 1.50% due 2033, detailing net proceeds of approximately $1,471.1 million, planned use of proceeds including existing debt repurchases, conversion terms, interest payment schedules, and redemption conditions.



Please wait processing your request...